MA33838B1 - Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase - Google Patents

Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase

Info

Publication number
MA33838B1
MA33838B1 MA34989A MA34989A MA33838B1 MA 33838 B1 MA33838 B1 MA 33838B1 MA 34989 A MA34989 A MA 34989A MA 34989 A MA34989 A MA 34989A MA 33838 B1 MA33838 B1 MA 33838B1
Authority
MA
Morocco
Prior art keywords
salt
relates
cloxylsramide
metrons
keynes
Prior art date
Application number
MA34989A
Other languages
Arabic (ar)
English (en)
Inventor
Renu Bhardwaj
Hanlan Liu
Chris Willis
Diane P Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33838(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA33838B1 publication Critical patent/MA33838B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La présente invention concerne le sel d'hémitartrate d'un composé répondant à la formule structurelle suivante : (hémitartrate de formule i), pouvant être employé dans des applications pharmaceutiques. Les formes cristallines uniques particulières de l'hémitartrate de formule i sont caractérisées par diverses propriétés et mesures physiques. En outre, la présente invention concerne également des méthodes de production d'hémitartrate de formule (i) cristallin et d'application à l'inhibition de la glucosylcéramide synthétase ou à la diminution des concentrations en glycosphingolipides chez des sujets pour le traitement de plusieurs pathologies. La présente invention concerne également des compositions pharmaceutiques.
MA34989A 2009-11-27 2012-06-20 Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase MA33838B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
PCT/US2010/057952 WO2011066352A1 (fr) 2009-11-27 2010-11-24 Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase

Publications (1)

Publication Number Publication Date
MA33838B1 true MA33838B1 (fr) 2012-12-03

Family

ID=43431870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34989A MA33838B1 (fr) 2009-11-27 2012-06-20 Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase

Country Status (41)

Country Link
US (6) US11458119B2 (fr)
EP (5) EP2504332B2 (fr)
JP (6) JP2013512252A (fr)
KR (5) KR20120115972A (fr)
CN (5) CN102712629B (fr)
AR (3) AR079152A1 (fr)
AU (3) AU2010324810B2 (fr)
BR (1) BR112012012947B8 (fr)
CA (3) CA3075788C (fr)
CL (2) CL2012001348A1 (fr)
CR (1) CR20120277A (fr)
CY (3) CY1115880T1 (fr)
DK (3) DK2796457T3 (fr)
DO (2) DOP2012000141A (fr)
EA (3) EA201890254A3 (fr)
EC (2) ECSP12011926A (fr)
ES (4) ES2875382T3 (fr)
GT (1) GT201200161A (fr)
HK (2) HK1172031A1 (fr)
HR (3) HRP20140780T4 (fr)
HU (2) HUE045784T2 (fr)
IL (4) IL310635A (fr)
LT (2) LT3133070T (fr)
MA (1) MA33838B1 (fr)
ME (1) ME02477B (fr)
MX (1) MX358345B (fr)
MY (2) MY192644A (fr)
NI (1) NI201200096A (fr)
NZ (3) NZ625712A (fr)
PE (2) PE20121337A1 (fr)
PH (1) PH12015502514A1 (fr)
PL (4) PL2504332T5 (fr)
PT (4) PT3133070T (fr)
RS (3) RS53503B2 (fr)
SG (2) SG10201800136QA (fr)
SI (3) SI3133070T1 (fr)
SM (1) SMT201600273B (fr)
TN (1) TN2012000237A1 (fr)
TW (3) TWI586663B (fr)
UA (1) UA113491C2 (fr)
WO (1) WO2011066352A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (fr) 2004-07-01 2006-01-19 University Of Pennsylvania Remplacement de proteines ciblees pour le traitement de maladies lysosomales
US11458119B2 (en) 2009-11-27 2022-10-04 Genzyme Corporation Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
ES2664844T3 (es) * 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
ES2791760T3 (es) 2011-09-07 2020-11-05 Sinai School Medicine Ceramidasa y diferenciación celular
WO2013078413A1 (fr) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulateurs du stockage lipidique
US9492514B2 (en) 2012-06-01 2016-11-15 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
MX2015012471A (es) 2013-03-14 2016-08-03 Icahn School Med Mount Sinai Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
TWI690511B (zh) * 2013-09-20 2020-04-11 美商拜奧馬林製藥公司 用於治療疾病之葡萄糖苷基腦醯胺（ｇｌｕｃｏｓｙｌｃｅｒａｍｉｄｅ）合成酶抑制劑
WO2016001885A2 (fr) * 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Forme amorphe d'hémitartrate d'eliglustat
EP3283483B1 (fr) 2015-04-14 2018-12-19 Sandoz AG Chlorhydrate d'éliglustat cristallin
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3377908B1 (fr) 2015-11-18 2020-08-05 Genzyme Corporation Biomarqueur de maladie polykystique des reins et utilisations associées
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (fr) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibiteurs de la synthase de glucosylcéramide pour le traitement de maladies du motoneurone
WO2018193090A2 (fr) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
AU2018283289B2 (en) * 2017-06-16 2021-03-25 Beta Pharma, Inc. Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
EP3664798A4 (fr) * 2017-08-08 2021-05-05 Kashiv Biosciences, LLC Composition pharmaceutique comprenant de l'éliglustat
US20200222310A1 (en) * 2017-08-08 2020-07-16 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
JP2021506789A (ja) * 2017-12-15 2021-02-22 ジェンザイム・コーポレーション ゴーシェ病を処置する方法
WO2019123476A1 (fr) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Prémélange d'éliglustat amorphe stable et son procédé de préparation
WO2019211778A2 (fr) * 2018-05-02 2019-11-07 Kashiv Biosciences, Llc Pro-médicaments d'eliglustat
AU2019276882A1 (en) * 2018-05-27 2021-01-14 Bioasis Technolgies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
AU676361B2 (en) 1993-08-13 1997-03-06 Seikagaku Corporation Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
CA2182485A1 (fr) 1994-02-02 1995-08-10 Yong Wei Composes et liposomes possedant des proprietes pharmaceutiques; methodesd'utilisation
AU698833B2 (en) 1994-06-10 1998-11-12 Seikagaku Corporation 2-acylaminopropanol compound and medical composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO1997010817A1 (fr) * 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Composes de type amino ceramide et leurs methodes d'utilisation therapeutiques
WO2001004108A1 (fr) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Composes de type amino-ceramide et procedes therapeutiques d'utilisation
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
AU756008B2 (en) 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
EP1384719A1 (fr) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibiteurs de l'enzyme synthetase de glucosyl-ceramide pour soigner le cancer, la sphingolipidose et les infections microbiennes
CA2378600A1 (fr) * 1999-07-09 2001-01-18 The Regents Of The University Of Michigan Composes de type amino-ceramide et procedes therapeutiques d'utilisation
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
IL152411A0 (en) 2000-04-24 2003-05-29 Teva Pharma Zolpidem hemitartrate
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
BR0206400A (pt) 2001-01-10 2005-01-18 Univ Michigan Compostos de amino ceramidas e seus usos em métodos terapêuticos
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
KR20030067755A (ko) 2001-01-18 2003-08-14 메르크 파텐트 게엠베하 글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질
ES2399323T3 (es) 2001-07-16 2013-03-27 Genzyme Corporation Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
EP1281755A3 (fr) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants du gène humain cyp2d6
DK2206702T3 (da) 2001-08-08 2012-02-13 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
AU2003251829B2 (en) 2002-07-09 2009-12-10 Radical Therapeutix Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
DE602005027308D1 (de) * 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
JP2008514731A (ja) 2004-09-30 2008-05-08 ヴァンダ ファーマシューティカルズ インコーポレイテッド イロペリドンの投与方法
MX2007004514A (es) 2004-10-13 2007-05-09 Pharmacia & Upjohn Co Llc Formas cristalinas de 3-[5-cloro-4-[(2,4-difluorobencil)oxi]-6 oxopirimidin-1(6h)-il]-n-(2-hidroxetil)-4-metilbenzamida.
JP2008519840A (ja) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
US20070088082A1 (en) * 2005-09-28 2007-04-19 Judith Aronhime Polymorphic forms of ladostigil tartrate
CN101277959A (zh) * 2005-10-03 2008-10-01 马林克罗特公司 制备唑吡坦半酒石酸盐和酒石酸盐多晶型的方法
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
EP2923699B1 (fr) 2006-05-09 2018-06-20 Genzyme Corporation Methodes pour traiter la steatose hepatique par inhibition de la synthese des glucosphingolipides
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (fr) 2006-12-08 2008-08-27 Zealand Pharma A/S Peptides PTH tronqués à formation cyclique
JP2010523578A (ja) * 2007-03-30 2010-07-15 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いるファブリー病の治療方法
US9056101B2 (en) 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US8304447B2 (en) * 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307180A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (fr) * 2008-03-20 2009-09-24 Genzyme Corporation Méthode de traitement d’un lupus avec des dérivés de céramide
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
US11458119B2 (en) 2009-11-27 2022-10-04 Genzyme Corporation Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
BR112012012617B8 (pt) 2009-11-27 2021-05-25 Adverio Pharma Gmbh processo para a produção de metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato
IN2014DN00145A (fr) 2011-06-21 2015-05-22 Novartis Ag
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (fr) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci

Also Published As

Publication number Publication date
ME02477B (fr) 2017-02-20
CA2781676A1 (fr) 2011-06-03
CR20120277A (es) 2012-09-05
US20160120842A1 (en) 2016-05-05
KR20220162824A (ko) 2022-12-08
DK2796457T3 (en) 2016-08-29
JP2015212291A (ja) 2015-11-26
NZ715108A (en) 2017-06-30
DOP2016000250A (es) 2017-02-15
EP2796457A1 (fr) 2014-10-29
SI2796457T1 (sl) 2016-10-28
TWI656873B (zh) 2019-04-21
IL260299A (en) 2018-08-30
PL2504332T3 (pl) 2014-10-31
EA201890254A3 (ru) 2019-02-28
MY192644A (en) 2022-08-29
CA3075788A1 (fr) 2011-06-03
US10888547B2 (en) 2021-01-12
RS54978B1 (sr) 2016-11-30
EP2504332A1 (fr) 2012-10-03
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
PL2796457T3 (pl) 2017-04-28
AR079152A1 (es) 2011-12-28
JP6452635B2 (ja) 2019-01-16
US11458119B2 (en) 2022-10-04
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
KR20180049255A (ko) 2018-05-10
DOP2012000141A (es) 2012-09-30
WO2011066352A8 (fr) 2011-08-11
HK1172031A1 (en) 2013-04-12
PT3599237T (pt) 2021-04-28
CN112521367B (zh) 2024-01-02
PT3133070T (pt) 2019-11-11
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
JP2019001809A (ja) 2019-01-10
CN112521366A (zh) 2021-03-19
RS53503B1 (en) 2015-02-27
JP6370264B2 (ja) 2018-08-08
SG10201407881WA (en) 2015-01-29
EA029990B1 (ru) 2018-06-29
ECSP18063798A (es) 2020-02-28
SMT201600273B (it) 2016-08-31
TWI586663B (zh) 2017-06-11
BR112012012947A2 (pt) 2017-03-01
CN105777707B (zh) 2020-10-13
DK2504332T3 (da) 2014-08-25
CL2012001348A1 (es) 2012-08-24
HUE029371T2 (en) 2017-02-28
SI3133070T1 (sl) 2019-11-29
HRP20140780T1 (en) 2014-11-07
HRP20140780T4 (hr) 2021-08-06
CN102712629B (zh) 2016-10-12
AU2017265180B2 (en) 2019-08-01
KR20150125734A (ko) 2015-11-09
IL310635A (en) 2024-04-01
EA201270646A1 (ru) 2013-01-30
AU2016202591A1 (en) 2016-05-19
MX2012006083A (es) 2012-06-19
CY1117996T1 (el) 2017-05-17
LT2796457T (lt) 2016-09-12
US20210369672A1 (en) 2021-12-02
BR112012012947B8 (pt) 2021-05-25
MY160542A (en) 2017-03-15
CL2016002589A1 (es) 2017-05-19
ECSP12011926A (es) 2012-07-31
UA113491C2 (xx) 2017-02-10
ES2875382T3 (es) 2021-11-10
AU2016202591B2 (en) 2017-11-30
CN112521367A (zh) 2021-03-19
SI2504332T2 (sl) 2021-08-31
AR121612A2 (es) 2022-06-22
CA3075788C (fr) 2021-12-21
EA201592195A1 (ru) 2016-04-29
IL283935A (en) 2021-07-29
ES2493940T3 (es) 2014-09-12
BR112012012947B1 (pt) 2021-04-06
PL3133070T3 (pl) 2020-01-31
EP3133070A1 (fr) 2017-02-22
US20130137743A1 (en) 2013-05-30
PL2504332T5 (pl) 2021-08-23
KR20200013105A (ko) 2020-02-05
CA3140959A1 (fr) 2011-06-03
EP3133070B1 (fr) 2019-08-14
JP7150528B2 (ja) 2022-10-11
PT2796457T (pt) 2016-07-14
DK2504332T4 (da) 2021-06-07
SG10201800136QA (en) 2018-02-27
US20230172903A1 (en) 2023-06-08
EP2504332B2 (fr) 2021-03-17
ES2586947T3 (es) 2016-10-19
IL219892A0 (en) 2012-07-31
JP2013512252A (ja) 2013-04-11
AU2010324810A1 (en) 2012-06-07
US20160166542A1 (en) 2016-06-16
JP2020189873A (ja) 2020-11-26
KR20120115972A (ko) 2012-10-19
EA201890254A2 (ru) 2018-10-31
HRP20161038T1 (hr) 2016-10-21
ES2754398T3 (es) 2020-04-17
LT3133070T (lt) 2019-11-11
TW201639562A (zh) 2016-11-16
TW201130822A (en) 2011-09-16
RS53503B2 (sr) 2021-07-30
DK3133070T3 (da) 2019-11-11
CA2781676C (fr) 2020-05-05
ES2493940T5 (es) 2021-11-23
HRP20191647T1 (hr) 2019-12-13
NZ600155A (en) 2014-10-31
EP3599237B1 (fr) 2021-03-24
PE20171255A1 (es) 2017-08-28
TW201737910A (zh) 2017-11-01
JP2023116764A (ja) 2023-08-22
TN2012000237A1 (en) 2013-12-12
PT2504332E (pt) 2014-09-02
EP3896069A1 (fr) 2021-10-20
CN102712629A (zh) 2012-10-03
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
HK1203485A1 (zh) 2015-10-30
EP2504332B1 (fr) 2014-06-04
WO2011066352A1 (fr) 2011-06-03
JP2016138124A (ja) 2016-08-04
EP2796457B1 (fr) 2016-05-18
CY1122698T1 (el) 2021-03-12
PL3599237T3 (pl) 2021-09-27
AU2017265180A1 (en) 2017-12-14
RS59543B1 (sr) 2019-12-31
NI201200096A (es) 2012-10-30
CN105753846B (zh) 2019-11-15
GT201200161A (es) 2014-01-27
HUE045784T2 (hu) 2020-01-28
EA023923B1 (ru) 2016-07-29
PH12015502514A1 (en) 2016-08-15
CY1115880T1 (el) 2017-01-25
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
SI2504332T1 (sl) 2014-09-30
EP3599237A1 (fr) 2020-01-29

Similar Documents

Publication Publication Date Title
MA33838B1 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
MX2009002171A (es) Derivados de triazol como inhibidores de cinasas.
WO2009066152A3 (fr) Inhibiteurs de ssao/vap-1 de type haloallylamines et leurs utilisations
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
UA99524C2 (ru) Триазолопроизводные, полезные для лечения болезней
EA201100503A1 (ru) Глюкозидные производные и их применения
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
NZ594854A (en) Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
IN2014DN05772A (fr)
MY148948A (en) Catecholamine derivatives and prodrugs thereof
WO2010142766A3 (fr) Dérivés de pyrimidine comme inhibiteurs de la zap-70
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
GB0514811D0 (en) Compounds
GB0609897D0 (en) Compounds
MX2007013305A (es) Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors